GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Other Operating Expense : ₹12,478 Mil (TTM As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Other Operating Expense?

GlaxoSmithKline Pharmaceuticals's Other Operating Expense for the three months ended in Mar. 2025 was ₹3,040 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was ₹12,478 Mil.

GlaxoSmithKline Pharmaceuticals's quarterly Other Operating Expense declined from Sep. 2024 (₹3,214 Mil) to Dec. 2024 (₹3,171 Mil) and declined from Dec. 2024 (₹3,171 Mil) to Mar. 2025 (₹3,040 Mil).

GlaxoSmithKline Pharmaceuticals's annual Other Operating Expense increased from Mar. 2023 (₹9,122 Mil) to Mar. 2024 (₹10,518 Mil) and increased from Mar. 2024 (₹10,518 Mil) to Mar. 2025 (₹12,478 Mil).

GlaxoSmithKline Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Other Operating Expense Chart

GlaxoSmithKline Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Other Operating Expense

Get a 7-Day Free Trial

9,076.12

8,783.70

9,121.52

10,517.67

12,477.80

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Operating Expense	Get a 7-Day Free Trial															3,235.10	3,052.50	3,214.30	3,171.40	3,039.60

GlaxoSmithKline Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹12,478 Mil.

GlaxoSmithKline Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (NSE:GLAXO) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

500660:India

Address

Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400030

Website

https://www.gsk-india.com

GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.

GlaxoSmithKline Pharmaceuticals Headlines

No Headlines